PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-21.98%
Both yoy net incomes decline, with GNPX at -5.52%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
22.78%
Some D&A expansion while GNPX is negative at -4.89%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
128.24%
SBC growth well above GNPX's 5.80%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-92.68%
Negative yoy working capital usage while GNPX is 174.97%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
314.60%
AP growth well above GNPX's 100.10%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
26.98%
Lower 'other working capital' growth vs. GNPX's 504.93%. David Dodd would see fewer unexpected short-term demands on cash.
-101.99%
Negative yoy while GNPX is 305.41%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-120.47%
Both yoy CFO lines are negative, with GNPX at -2.02%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
72.96%
CapEx growth well above GNPX's 26.55%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.96%
Lower net investing outflow yoy vs. GNPX's 247.62%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
86.96%
Debt repayment growth of 86.96% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-90.54%
Negative yoy issuance while GNPX is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.